PubMed 22962027 TB-4 Phase 1 human safety first-in-human randomized, double-blind, single- and multiple-dose Phase 1 of recombinant human thymosin 4 in healthy volunteers, no serious adverse events: PubMed 34346165
This decrease was also magnified as CPT code 61715 is a low volume service where small shifts in the specialty reporting can have an outsized effect on valuation
This text was inadvertently included in the CY 2025 PFS final rule (89 FR 98583) and needs to be removed because the statutory provision governing the payment amount in the payment amount benchmark quarter, section 1847A(i)(3)(C)(i) of the Act, does not limit that amount to payment amounts determined under section 1847A of the Act and because the payment limits for some Part B rebatable drugs are not determined under section 1847A of the Act
Like how medical professionals utilize knee OA injection, they may recommend HA shoulder joint injections when first-line therapies and oral medications have not affected individuals
Practical use requires individualized plans that cover administration route, dosing, cycling, and regular monitoring through semen analysis and hormone tests to track safety and effectiveness
